Compare · ARGX vs SRRK
ARGX vs SRRK
Side-by-side comparison of argenx SE (ARGX) and Scholar Rock Holding Corporation (SRRK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and SRRK operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $53.41B, about 8.4x SRRK ($6.33B).
- Over the past year, ARGX is up 52.5% and SRRK is up 29.8% - ARGX leads by 22.7 points.
- SRRK has been more active in the news (10 items in the past 4 weeks vs 3 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 19 for SRRK).
- Company
- argenx SE
- Scholar Rock Holding Corporation
- Price
- $861.30+0.30%
- $52.84+2.29%
- Market cap
- $53.41B
- $6.33B
- 1M return
- -1.91%
- +15.82%
- 1Y return
- +52.49%
- +29.82%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2018
- News (4w)
- 3
- 10
- Recent ratings
- 25
- 19
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Scholar Rock Holding Corporation
Scholar Rock Holding Corporation, a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, a novel inhibitor of the activation of latent myostatin that has completed the Phase II clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase I clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Latest ARGX
- argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
- SEC Form 6-K filed by argenx SE
- argenx to Host Autoimmune Myositis R&D Webinar
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Latest SRRK
- Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Scholar Rock to Report Second Quarter 2026 Financial Results on August 6, 2026
- Director Burow Kristina sold $164,064 worth of shares (3,053 units at $53.74), decreasing direct ownership by 3% to 114,657 units (SEC Form 4) (tax liability)
- Director Flier Jeffrey S. sold $164,490 worth of shares (3,053 units at $53.88), decreasing direct ownership by 10% to 27,856 units (SEC Form 4) to cover withholding tax
- Director Gilman Michael sold $137,058 worth of shares (2,544 units at $53.87), decreasing direct ownership by 4% to 59,511 units (SEC Form 4) (tax withholding)
- Director Reed Joshua sold $164,067 worth of shares (3,053 units at $53.74), decreasing direct ownership by 14% to 19,518 units (SEC Form 4) to cover taxes
- Director Peng Katie sold $293,405 worth of shares (5,446 units at $53.88), decreasing direct ownership by 14% to 34,301 units (SEC Form 4) (withholding tax)
- SEC Form 144 filed by Scholar Rock Holding Corporation
- SEC Form 144 filed by Scholar Rock Holding Corporation
- Scholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHD